Evidence map›Paper›PMID 21655917›Full record

ArticleInvestigational new drugs2012

Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor.

Lih-Ching Hsu, David E Durrant, Ching-Chun Huang, Nai-Wen Chi, Riccardo Baruchello, Riccardo Rondanin, Cinzia Rullo, Paolo Marchetti, Giuseppina Grisolia, Daniele Simoni and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Lih-Ching HsuSchool of Pharmacy, National Taiwan University, 12F, No 1, Section 1, Jen-Ai Road, Taipei 10051, Taiwan. lhsu@ntu.edu.tw
David E Durrant
Ching-Chun Huang
Nai-Wen Chi
Riccardo Baruchello
Riccardo Rondanin
Cinzia Rullo
Paolo Marchetti
Giuseppina Grisolia
Daniele Simoni
Ray M Lee
University of Ferrara · ITNational Taiwan University · TWVA San Diego Healthcare System · USVirginia Commonwealth University · US

Funding

Regulation of BRCA1 Function by Protein Phosphatase 1R01CA111436 · NCI · NATIONAL TAIWAN UNIVERSITY · PI HSU, LIH-CHING · 2005 to 2009
$706k
NCI NIH HHS R01CA111436
6 · The paper itself

Abstract

Hemiasterlins are cytotoxic tripeptides with antimicrotubule activity originally isolated from marine sponges. We have developed new hemiasterlin derivatives BF65 and BF78 that are highly potent to induce cancer cell death in the low nanomolar range. Examination of their mechanisms of cell cycle arrest and disruption of microtubules revealed an unusual characteristic in addition to anti-tubulin effect. Immunofluorescence staining revealed that A549 lung carcinoma cells treated with BF65 or BF78 exhibited both monopolar and multipolar mitotic spindles. Centrosomes were separated with short spindle microtubules in cells with multipolar spindles. In vitro tubulin polymerization assay confirmed that both BF65 and BF78 were highly potent to inhibit tubulin polymerization. These two compounds induced the formation of monoastral spindles suggesting that they might be inhibitors of mitotic kinesins such as KSP/Eg5. However, kinetic measurement of microtubule activated kinesin ATPase activity demonstrated that unlike the positive control monastrol, neither BF65 nor BF78 suppressed KSP/Eg5 activity. Hence the effect may be a variant form of tubulin inhibition. Similar to vinca alkaloids, BF compounds synergized with a colchicine site microtubule inhibitor stilbene 5c both in vitro and in vivo, which may provide a potential drug combination in the future clinical application.

Indexed as

AnimalsAntineoplastic AgentsCell CycleCell DeathCell Line, TumorDrug SynergismFluorescent Antibody TechniqueHumansKinesinsMiceMicrotubulesOligopeptidesPolymerizationSignal TransductionSpindle ApparatusStilbenesAntineoplastic Agentscis-3,4',5-trimethoxy-3'-aminostilbenehemiasterlinKinesinsOligopeptidesStilbenesTubulinTubulin Modulators

Identifiers

PMID21655917
OpenAlexW2014789297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.